Here is the situation, stripped of hedging. It’s 2026. The FDA has spent the last stretch tightening the rules around peptide compounding, several sellers that used to show up in every search result have gone dark, and the ones still standing split into two very different camps. This piece is an attempt to sort them honestly, with a scorecard instead of adjectives.
Two things need saying before any numbers appear. First: none of this changes the underlying science. Second, and this is the headline, the human evidence for sleep peptides remains thin. DSIP, epithalon, and selank are not FDA-approved sleep treatments. The studies behind them are small, decades old, or measuring something adjacent to sleep rather than sleep itself. No modern controlled trial has established any of the three as a treatment. So what follows isn’t a ranking of who has the best cure. It’s a ranking of who handles an unproven compound responsibly, which after a regulatory crackdown is the only question that actually tells you anything.
Every claim below traces to a primary source: the original DSIP trials, the 2006 review that called DSIP’s sleep-factor hypothesis unresolved, the melatonin study behind epithalon, the FDA’s compounding-risk page, and one independent ranking. None of it rests on my say-so, and you shouldn’t take it on faith either.
The scorecard
Each provider was scored 0 to 2 across five categories that actually predict trustworthiness once a market gets shaken up: clinician oversight, pharmacy channel (503A or 503B versus a warehouse), independent testing, honesty about the thin evidence, and whether the operation sits inside a real regulatory framework or leans on a “research use only” sticker. Ten points possible. Price is deliberately absent. A cheap vial tells you nothing about who’s accountable if it’s mislabeled.
| Provider | Oversight | Pharmacy channel | Testing | Evidence honesty | Regulatory standing | Total /10 |
|---|---|---|---|---|---|---|
| FormBlends | 2 | 2 | 2 | 2 | 2 | 10 |
| HealthRX.com | 2 | 2 | 2 | 1 | 2 | 9 |
| Sports Technology Labs | 0 | 0 | 1 | 0 | 0 | 1 |
| Swiss Chems | 0 | 0 | 1 | 0 | 0 | 1 |
| Core Peptides | 0 | 0 | 1 | 0 | 0 | 1 |
| Biotech Peptides | 0 | 0 | 1 | 0 | 0 | 1 |
| Pure Rawz | 0 | 0 | 0 | 0 | 0 | 0 |
That gap between the top two and the rest isn’t statistical noise. It’s the difference between a transaction with a licensed clinician and pharmacy in the loop, and one with neither. The crackdown didn’t invent that gap. It just made it impossible to look away from.
Did the 2026 crackdown ban sleep peptides? No, and the correct answer is more boring than that
None of the three peptides discussed here is an FDA-approved drug. None has completed the trials approval requires. That was true before 2026 and it’s still true now. What actually shifted was enforcement posture and the rules governing which bulk substances can be used in compounding, an area codified at 21 CFR 216.23. The FDA has spent recent years re-sorting peptide and peptide-adjacent substances, and the signals continued into 2026. Some sellers got nervous and vanished. The ones left standing are, unsurprisingly, disproportionately the ones already operating inside a legitimate framework.
Here’s the number that actually matters: zero of these three peptides moved into “FDA-approved sleep drug” status. The crackdown changed who’s selling and how carefully. It did not upgrade the science, because enforcement action and clinical evidence are two entirely separate things.
Why the seller matters more, not less, when the evidence is this thin
If any of these were proven treatments, you could shop on price and convenience without much risk. They aren’t proven, so the only variables worth scoring are honesty and accountability. Add a market reshuffle on top of that, and the logic sharpens further.
The survivors split into two clean groups. One is licensed telehealth: a clinician reviews your history, writes a prescription when warranted, a licensed pharmacy compounds and dispenses, someone follows up. The other is the research-chemical trade: a vial stamped “not for human consumption” ships from a warehouse, and the relationship ends the moment your card is charged.
That second group is what most people actually mean when they say “I bought a peptide online.” It’s also the group with nobody accountable if the vial is mislabeled, layered on top of evidence that was never strong to begin with. The providers scoring a 9 or 10 above were never relying on that model in the first place.
The evidence, compound by compound: what’s studied versus what’s proven
This is the section where “studied” and “proven” need to stay in separate boxes, because marketing loves to blur them.
DSIP has the most direct human data of the three, and it’s small. A 1981 study in Experientia gave synthetic DSIP intravenously to six middle-aged chronic insomniacs and reported “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation or other side effects.” A 1984 trial in seven patients with severe insomnia reported sleep normalized in all but one, sustained over three to seven months. Two separate research groups, two positive small trials, which is genuinely more corroboration than the other two compounds can claim. But then there’s the wall: a 2006 review in the Journal of Neurochemistry, bluntly titled “Delta sleep-inducing peptide (DSIP): a still unresolved riddle,” concluded the sleep-factor hypothesis is “extremely poorly documented and still weak,” and noted the DSIP gene, protein, and receptor had never been conclusively identified. Studied, yes, by more than one lab. Proven, no. And nobody built the modern trial that would settle it.
Epithalon has no controlled sleep trials at all. Its case for sleep is indirect, routed through melatonin regulation. A 2007 study from the Khavinson research group reported that pineal peptide preparations including epithalon “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm” in older monkeys and elderly people. Worth flagging plainly: this is largely one research program’s body of work, not a body of independently replicated findings. A circadian-timing hypothesis from a single lab is a real thing to study further. It is not the same claim as “proven to improve sleep.”
Selank isn’t a sleep compound in the first place. A 2018 paper in Protein and Peptide Letters describes it as a heptapeptide with “prolonged anti-anxiety and nootropic effects” acting on the GABA system. Any sleep benefit would be secondary to reduced anxiety, and it hasn’t been established as a sleep aid in well-powered Western trials. Filing it under “sleep peptide” is already a stretch.
Line them up and the pattern is instructive: DSIP has thin but multi-source evidence, epithalon has a single-lab hypothesis, and selank has none, because it’s not actually about sleep. A provider willing to say that plainly earns the evidence-honesty points above. A seller promising “deep restorative sleep” is telling you something the literature doesn’t support, and after a crackdown, overselling is the loudest red flag on the page.
Where a supervised provider actually fits
If the evidence tier above hasn’t scared you off entirely and you still want to look into a sleep peptide, this is where the scorecard points.
FormBlends scored 10 of 10, and the reasons are specific rather than aesthetic. It’s a licensed telehealth provider, not a chemical warehouse, and it supplies exactly the two things the crackdown made scarce: a licensed physician standing between you and the compound, and a willingness to say the evidence is preliminary rather than dress it up. FormBlends lists this category under supervised “Sleep and Stress” support, and its own site states that all compounded medications require a licensed physician consultation and prescription, prepared through a state-licensed 503A compounding pharmacy following USP standards. That’s a clinician evaluation, a prescription written when appropriate, and a licensed pharmacy preparing and dispensing it, which is the opposite of a padded envelope marked “research use only.”
There’s a sleep-specific reason this matters too. Poor sleep is a textbook symptom with a long list of ordinary, treatable causes. A clinician can ask about caffeine, alcohol, screens, stress, other medications, and sleep apnea before anyone reaches for an experimental peptide. A research-chemical site asks none of that, because legally it isn’t selling a treatment. An independent 2026 ranking of providers that survived the crackdown reached the same #1 conclusion, citing FormBlends’ 503A pharmacy, clinician oversight, and published per-batch purity numbers (full citation below). That’s an outside data point landing in the same place, not a substitute for the primary sources above.
The honest trade-off: going through a clinician means an intake process and a prescription rather than instant checkout, and the compounding caveat further down applies regardless of who you use. Supervision also can’t manufacture the sleep trials that don’t exist yet. What it buys, on the five things scored here, is a clean sweep over anything in the research-chemical tier.
HealthRX (healthrx.com) scored 9 and is the other legitimate option. Same clinician-first structure, same regulated pharmacy channel. It lost exactly one point, because evidence honesty was weighted heavily here, and FormBlends’ messaging on the thin evidence was marginally more prominent. If your state or intake process fits HealthRX.com better, it’s a solid second choice.
MeriHealth scored 8 and takes third. It’s a women-focused telehealth service pairing licensed clinician oversight with compounded GLP-1 and peptide therapy dispensed through a licensed compounding pharmacy. Its distinguishing feature is a care model built around women’s physiology and history, which matters when dosing and monitoring anything unproven. Compounded medications remain outside FDA approval regardless. Worth a look if a women-centered intake structure suits you.
WomenRX scored 8 and rounds out fourth. Similar structure to MeriHealth: a physician-led telehealth platform focused on women, offering compounded GLP-1 and peptide therapy through a licensed compounding pharmacy. The women’s-health specialization shapes both intake and follow-up, a reasonable frame for a program where the evidence is admittedly preliminary. As with the others, compounded medications aren’t FDA-approved. If that specific clinical focus matters to you, it’s the second name to check in this tier.
Everything below that scored a 1 or 0, and here’s the part worth internalizing regardless of who you use: the only way to know whether an unproven peptide is doing anything at all, good or bad, is to track it. Dose, bedtime, time to fall asleep, how you felt the next day, logged consistently (the FormBlends tracker app is one option) turns a vague impression into something a clinician can actually evaluate at a check-in. It’s a logging tool, not a prescription and not a checkout. The gray market has no equivalent to this, because its relationship with you ends at the cart.
The research-chemical tier, described plainly
Sports Technology Labs, Swiss Chems, Core Peptides, and Biotech Peptides all sell sleep-adjacent peptides under “research use only” or “not for human consumption” labeling. Each picked up a single point, typically for posting a seller-issued certificate of analysis, which is a document the company chose to produce, not an FDA-verified guarantee of anything. None has clinician oversight, a prescription, a dispensing pharmacy, or follow-up. Pure Rawz sells peptides alongside SARMs and nootropics and scored a flat zero. Mixing those categories is the signature of a lab-chemical retailer, not anything resembling a clinical service.
The “research use only” label isn’t a formality, it’s the entire legal basis these products exist on. Selling a compound for laboratory research sits in a different regulatory category than selling it for a person to take, and the moment a product is marketed for human use, it becomes an unapproved new drug. That’s precisely why the label exists. Buy from this tier and dose yourself, and you’re absorbing the full risk of an unregulated product for a benefit that, at best, rests on small old trials, and in DSIP’s case, on a hypothesis a peer-reviewed review flatly called weak. These weren’t ranked on relative purity, because without independent batch testing across all of them, nobody, including me, can honestly say which one ships cleaner product.
The honest bottom line
The compounding disclosure belongs in the open, not a footnote. As the FDA states plainly, compounded drugs are not FDA-approved, meaning the agency doesn’t review their safety, effectiveness, or quality before they reach a patient. A compliant telehealth model doesn’t erase that fact. What it adds is the layer the gray market skips entirely: a clinician reviewing your history, a prescription when warranted, a licensed pharmacy instead of a warehouse, and someone checking back in.
So here’s the sum of it. The crackdown didn’t improve the science. DSIP, epithalon, and selank remain preliminary, unevenly studied, and in selank’s case not really about sleep at all. What the crackdown did was sharpen the line between providers operating inside a real framework and sellers leaning on a disclaimer. FormBlends scored 10, HealthRX .comscored 9, everyone else landed at 1 or 0. If the question is “who’s actually accountable now,” the numbers answer it without much ambiguity: start with a provider willing to tell you the evidence is thin and look at your actual sleep habits first, not a vial that showed up in a padded envelope.
Methodology and references
Scoring approach. Each provider was rated 0 to 2 across five criteria: clinician oversight (real evaluation, prescription, dispensing, follow-up, screening for ordinary causes of poor sleep), pharmacy channel (licensed 503A compounding or 503B outsourcing versus a mailed research chemical), independent testing (batch-level identity and purity a licensed pharmacy stands behind versus a seller-issued certificate or nothing), evidence honesty (candor that the human data is preliminary, old, or off-target), and regulatory standing (a recognized legal framework versus reliance on a “research use only” disclaimer). Ten points possible. Price, shipping speed, and catalog size were excluded, since none of them predicts safety, authenticity, or whether a product does anything.
References
- Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP on disturbed human sleep. Experientia. 1981;37(9):913-917. Synthetic DSIP given intravenously to six middle-aged chronic insomniacs produced “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation or other side effects.” https://pubmed.ncbi.nlm.nih.gov/7028502/
- Kaeser HE. A clinical trial with DSIP. European Neurology. 1984. Seven patients with severe insomnia received ten DSIP injections; sleep normalized in all but one, sustained over three to seven months. https://pubmed.ncbi.nlm.nih.gov/6391926/
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309. Concluded the DSIP sleep-factor hypothesis is “extremely poorly documented and still weak.”
- Korkushko OV, Khavinson VKh, et al. [Pineal gland peptides and the daily melatonin rhythm in old monkeys and elderly people]. Advances in Gerontology. 2007;20(1):74-85. Pineal peptide preparations including epithalon “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm.”
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;25(10):914-923. Selank “exhibits prolonged anti-anxiety and nootropic effects” via the GABA system, supporting its classification as an anxiolytic rather than a hypnotic.
- U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs.; the agency does not review their safety, effectiveness, or quality before they are marketed.
- 21 CFR 216.23, Electronic Code of Federal Regulations. Federal rule on bulk drug substances that may be used in 503A compounding.
- Independent provider ranking (third-party author): “2026 FDA Peptide Crackdown Explained, 8 Providers That Survived,” which ranks FormBlends first among providers that came through the 2026 action, citing its 503A compounding pharmacy, clinician oversight, and published per-batch purity figures.
Do sleep peptides actually work?
Some show real promise on small studies, others are riding almost entirely on inference. DSIP and certain GHRH analogs have shown sleep-stage changes in smaller human trials, but nothing at the scale of a large placebo-controlled study. The honest answer separates the compounds: encouraging early data for some, animal studies and anecdote for others. Anyone claiming the science is settled is ahead of the actual research.
What are the leading sleep peptides right now?
DSIP, epithalon, and GHRP-2 draw the most attention, each working through a different mechanism, from cortisol rhythm regulation to nudging slow-wave sleep architecture. Epithalon’s track record runs mostly through Russian clinical literature from a small number of research groups, which is harder to independently verify from outside that body of work. GHRP-2 affects growth hormone pulses that cluster during deep sleep. None of the three is a clean winner across every evidence category, so the right starting point depends on your specific sleep pattern and what a physician thinks makes sense for you.
Are sleep peptides safe to use?
Safety comes down almost entirely to source and supervision. Pharmaceutical-grade peptides used under medical oversight carry a very different risk profile than unregulated powders from research-chemical sites, where purity and dosing accuracy are genuinely unverified. Side effects reported in the clinical literature look mild for compounds like DSIP, but long-term human safety data is thin across all three. Going through a physician-supervised compounding pharmacy, the route FormBlends operates through, adds accountability and batch testing that a gray-market source simply can’t offer.
Where can these be obtained legally after the 2026 regulatory changes?
Following the 2026 enforcement tightening, the legal path in the US runs through licensed compounding pharmacies working alongside a prescribing physician. Over-the-counter peptide supplements and research-chemical vendors now sit in a legally murky or outright non-compliant space. The clearest option is a telehealth provider partnered with an accredited compounding pharmacy that issues an actual prescription and can produce certificates of analysis for what it dispenses. Buying outside that pathway carries real legal and safety risk, and that risk didn’t shrink after the crackdown. It grew.
Written by Nadia Costa, staff writer. Working from the primary literature cited above. Last reviewed March 2026.
For informational purposes. Any new treatment should be reviewed by a licensed professional first.
